Sotyktu — Total Revenues
Bristol-Myers Squibb Sotyktu — Total Revenues increased by 14.3% to $80.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 21.2%, from $66.00M to $80.00M. Over 2 years (FY 2022 to FY 2024), Sotyktu — Total Revenues shows an upward trend with a 454.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration and physician adoption of the therapy, while a decrease may signal competitive pressure or challenges in patient access and reimbursement.
Detailed definition
This metric represents the total global net sales generated from the commercialization of Sotyktu, a selective tyrosine...
Peer comparison
Comparable to revenue metrics for specialized immunology or dermatology blockbusters at peer pharmaceutical companies, often evaluated against consensus growth estimates for new product launches.
bmy_segment_sotyktu_total_revenuesHistorical Data
| Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $1.00M | $7.00M | $16.00M | $25.00M | $66.00M | $63.00M | $44.00M | $53.00M | $66.00M | $83.00M | $55.00M | $70.00M | $80.00M |
| QoQ Change | — | — | — | — | +600.0% | +128.6% | +56.3% | +164.0% | -4.5% | -30.2% | +20.5% | +24.5% | +25.8% | -33.7% | +27.3% | +14.3% |
| YoY Change | — | — | — | — | — | — | — | >999% | +800.0% | +175.0% | +112.0% | +0.0% | +31.7% | +25.0% | +32.1% | +21.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's sotyktu — total revenues?
- Bristol-Myers Squibb (BMY) reported sotyktu — total revenues of $80.00M in Q3 2025.
- How has Bristol-Myers Squibb's sotyktu — total revenues changed year-over-year?
- Bristol-Myers Squibb's sotyktu — total revenues increased by 21.2% year-over-year, from $66.00M to $80.00M.
- What is the long-term trend for Bristol-Myers Squibb's sotyktu — total revenues?
- Over 2 years (2022 to 2024), Bristol-Myers Squibb's sotyktu — total revenues has grown at a 454.5% compound annual growth rate (CAGR), from $8.00M to $246.00M.
- What does sotyktu — total revenues mean?
- The total revenue generated from the sales of the drug Sotyktu.